Flow Cytometry Shared Resource was established in 2004 to provide ready and affordable access to state-of- the-art multi-parameter cell analysis and sorting capabilities. This facility is comprised of a large number and variety of flow cytometry instruments that quantify the fluorescence of individual cells, typically following staining with specific antibodies. Flow cytometry has become an important tool in cancer research for many different purposes. Some important applications include the immune profiling of tumor microenvironment and the phenotyping of cancer cells. Cell sorting by Flow Cytometry is critical for the purification of cells for genomics, proteomics, metabolomics, or the isolation of tumor stem cells. This institutional resource serves the entire Yale School of Medicine (YSM) campus, including Yale Cancer Center (YCC), and thus has a critical mass of users supporting these large and expensive instruments. During the most recent funding period, 197 laboratories have used Flow Cytometry. Ninety-four of these users (48%) were YCC members. This Shared Resource was most widely used by the Genomics, Genetics and Epigenetics (GGE) and the Cancer Immunology (CI) Research Programs. A wide variety of assays are performed, and the laboratory also offers consulting on experimental protocols with its experienced full-time director. Flow cytometry has multiple applications in cancer research. For example, as the pace of research into cancer immunology and biologic therapies increases, defining the functional and phenotypic heterogeneity of mixed cell populations will continue to be a critical technology in cancer research. Flow cytometry is not only essential for cancer immunology research, but also empowers numerous other types of studies such as oncogenesis, cell signaling events, preclinical models, the assessment of therapeutic efficacy, gene editing using CRISPR and of course, cell sorting for genomic and RNA sequencing. Clearly, Flow Cytometry is vital to a number of programs within YCC.
The Specific Aims of Flow Cytometry are to: (1) Provide flow cytometry services that are of high quality, readily available, and at reasonable cost; (2) Educate the YCC community on the applications of flow cytometry in medical research; and (3) Collaborate with YCC investigators in the development of new applications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-41
Application #
9989590
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
41
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Sarma, Elizabeth A; Kawachi, Ichiro; Poole, Elizabeth M et al. (2018) Social integration and survival after diagnosis of colorectal cancer. Cancer 124:833-840
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Zhang, Jinhua; Song, Kun; Wang, Jun et al. (2018) S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. Oncoimmunology 7:e1296996
Kelada, Olivia J; Decker, Roy H; Nath, Sameer K et al. (2018) High Single Doses of Radiation May Induce Elevated Levels of Hypoxia in Early-Stage Non-Small Cell Lung Cancer Tumors. Int J Radiat Oncol Biol Phys 102:174-183
Powles, Ryan L; Redmond, David; Sotiriou, Christos et al. (2018) Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol 4:e181564
Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011

Showing the most recent 10 out of 675 publications